IDEXX LABORATORIES INC (IDXX) Stock Fundamental Analysis
NASDAQ:IDXX • US45168D1046
649.23 USD
+26.1 (+4.19%)
At close: Feb 24, 2026
649.23 USD
0 (0%)
After Hours: 2/24/2026, 8:00:02 PM
Overall IDXX gets a fundamental rating of 7 out of 10. We evaluated IDXX against 185 industry peers in the Health Care Equipment & Supplies industry. IDXX gets an excellent profitability rating and is at the same time showing great financial health properties. IDXX has a correct valuation and a medium growth rate. These ratings would make IDXX suitable for quality investing!
1. Profitability
1.1 Basic Checks
- IDXX had positive earnings in the past year.
- IDXX had a positive operating cash flow in the past year.
- Each year in the past 5 years IDXX has been profitable.
- In the past 5 years IDXX always reported a positive cash flow from operatings.
1.2 Ratios
- The Return On Assets of IDXX (30.34%) is better than 100.00% of its industry peers.
- Looking at the Return On Equity, with a value of 65.81%, IDXX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- The Return On Invested Capital of IDXX (40.35%) is better than 100.00% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for IDXX is significantly above the industry average of 8.75%.
- The last Return On Invested Capital (40.35%) for IDXX is above the 3 year average (37.60%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROIC | 40.35% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.6%
ROIC(5y)38.02%
1.3 Margins
- Looking at the Profit Margin, with a value of 24.65%, IDXX belongs to the top of the industry, outperforming 95.68% of the companies in the same industry.
- IDXX's Profit Margin has improved in the last couple of years.
- IDXX's Operating Margin of 31.34% is amongst the best of the industry. IDXX outperforms 98.92% of its industry peers.
- In the last couple of years the Operating Margin of IDXX has grown nicely.
- The Gross Margin of IDXX (61.72%) is better than 64.86% of its industry peers.
- IDXX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% |
OM growth 3Y5.66%
OM growth 5Y4.24%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IDXX is creating value.
- The number of shares outstanding for IDXX has been reduced compared to 1 year ago.
- Compared to 5 years ago, IDXX has less shares outstanding
- The debt/assets ratio for IDXX has been reduced compared to a year ago.
2.2 Solvency
- IDXX has an Altman-Z score of 22.16. This indicates that IDXX is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of IDXX (22.16) is better than 96.22% of its industry peers.
- IDXX has a debt to FCF ratio of 1.04. This is a very positive value and a sign of high solvency as it would only need 1.04 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 1.04, IDXX belongs to the top of the industry, outperforming 90.27% of the companies in the same industry.
- IDXX has a Debt/Equity ratio of 0.53. This is a neutral value indicating IDXX is somewhat dependend on debt financing.
- IDXX's Debt to Equity ratio of 0.53 is in line compared to the rest of the industry. IDXX outperforms 40.54% of its industry peers.
- Even though the debt/equity ratio score it not favorable for IDXX, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Altman-Z | 22.16 |
ROIC/WACC4.1
WACC9.83%
2.3 Liquidity
- A Current Ratio of 1.18 indicates that IDXX should not have too much problems paying its short term obligations.
- With a Current ratio value of 1.18, IDXX is not doing good in the industry: 82.16% of the companies in the same industry are doing better.
- IDXX has a Quick Ratio of 1.18. This is a bad value and indicates that IDXX is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Quick ratio of IDXX (0.87) is worse than 81.62% of its industry peers.
- IDXX does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
- IDXX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.18%, which is quite good.
- IDXX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.26% yearly.
- The Revenue has grown by 10.42% in the past year. This is quite good.
- The Revenue has been growing by 9.72% on average over the past years. This is quite good.
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
3.2 Future
- Based on estimates for the next years, IDXX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.75% on average per year.
- The Revenue is expected to grow by 9.46% on average over the next years. This is quite good.
EPS Next Y13.36%
EPS Next 2Y13.1%
EPS Next 3Y13.3%
EPS Next 5Y13.75%
Revenue Next Year9.11%
Revenue Next 2Y8.86%
Revenue Next 3Y8.98%
Revenue Next 5Y9.46%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 49.67 indicates a quite expensive valuation of IDXX.
- Compared to the rest of the industry, the Price/Earnings ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 68.65% of the companies listed in the same industry.
- When comparing the Price/Earnings ratio of IDXX to the average of the S&P500 Index (26.98), we can say IDXX is valued expensively.
- A Price/Forward Earnings ratio of 43.82 indicates a quite expensive valuation of IDXX.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 68.11% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 28.01, IDXX is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.67 | ||
| Fwd PE | 43.82 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, IDXX is valued a bit cheaper than 67.57% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, IDXX is valued a bit cheaper than 72.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 55.14 | ||
| EV/EBITDA | 36.06 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IDXX does not grow enough to justify the current Price/Earnings ratio.
- IDXX has an outstanding profitability rating, which may justify a higher PE ratio.
- IDXX's earnings are expected to grow with 13.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.72
PEG (5Y)3.48
EPS Next 2Y13.1%
EPS Next 3Y13.3%
5. Dividend
5.1 Amount
- No dividends for IDXX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
649.23
+26.1 (+4.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-02 2026-02-02/bmo
Earnings (Next)04-29 2026-04-29/bmo
Inst Owners94.94%
Inst Owner Change11.39%
Ins Owners0.21%
Ins Owner Change2.75%
Market Cap51.84B
Revenue(TTM)4.30B
Net Income(TTM)1.03B
Analysts80.91
Price Target781.34 (20.35%)
Short Float %2.29%
Short Ratio3.54
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.14%
Min EPS beat(2)6.47%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)5.72%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.83%
EPS beat(12)12
Avg EPS beat(12)4.67%
EPS beat(16)14
Avg EPS beat(16)4.04%
Revenue beat(2)2
Avg Revenue beat(2)1.45%
Min Revenue beat(2)1.03%
Max Revenue beat(2)1.88%
Revenue beat(4)3
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)-1.06%
Revenue beat(16)4
Avg Revenue beat(16)-1.1%
PT rev (1m)-0.28%
PT rev (3m)1.06%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)0.06%
EPS NY rev (1m)0.19%
EPS NY rev (3m)2.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)2.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.67 | ||
| Fwd PE | 43.82 | ||
| P/S | 12.44 | ||
| P/FCF | 55.14 | ||
| P/OCF | 47.65 | ||
| P/B | 33.21 | ||
| P/tB | 50.2 | ||
| EV/EBITDA | 36.06 |
EPS(TTM)13.07
EY2.01%
EPS(NY)14.82
Fwd EY2.28%
FCF(TTM)11.77
FCFY1.81%
OCF(TTM)13.63
OCFY2.1%
SpS52.19
BVpS19.55
TBVpS12.93
PEG (NY)3.72
PEG (5Y)3.48
Graham Number75.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROCE | 61.18% | ||
| ROIC | 40.35% | ||
| ROICexc | 43.87% | ||
| ROICexgc | 56.38% | ||
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% | ||
| FCFM | 22.56% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.6%
ROIC(5y)38.02%
ROICexc(3y)42.72%
ROICexc(5y)42.26%
ROICexgc(3y)50.78%
ROICexgc(5y)53.04%
ROCE(3y)53.41%
ROCE(5y)55.15%
ROICexgc growth 3Y-1.85%
ROICexgc growth 5Y-3.56%
ROICexc growth 3Y7.2%
ROICexc growth 5Y1.43%
OM growth 3Y5.66%
OM growth 5Y4.24%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
F-Score8
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Debt/EBITDA | 0.57 | ||
| Cap/Depr | 105.48% | ||
| Cap/Sales | 3.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 75.23% | ||
| Profit Quality | 91.51% | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 22.16 |
F-Score8
WACC9.83%
ROIC/WACC4.1
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)3.3%
Cap/Sales(5y)3.67%
Profit Quality(3y)93.71%
Profit Quality(5y)84.62%
High Growth Momentum
Growth
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
EPS Next Y13.36%
EPS Next 2Y13.1%
EPS Next 3Y13.3%
EPS Next 5Y13.75%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
Revenue Next Year9.11%
Revenue Next 2Y8.86%
Revenue Next 3Y8.98%
Revenue Next 5Y9.46%
EBIT growth 1Y17.46%
EBIT growth 3Y14.66%
EBIT growth 5Y14.37%
EBIT Next Year22.21%
EBIT Next 3Y14.34%
EBIT Next 5Y15.18%
FCF growth 1Y18.62%
FCF growth 3Y40.13%
FCF growth 5Y14.37%
OCF growth 1Y18.68%
OCF growth 3Y29.59%
OCF growth 5Y12.77%
IDEXX LABORATORIES INC / IDXX FAQ
What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to IDXX.
What is the valuation status of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.
Can you provide the profitability details for IDEXX LABORATORIES INC?
IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.
What are the PE and PB ratios of IDEXX LABORATORIES INC (IDXX) stock?
The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 49.67 and the Price/Book (PB) ratio is 33.21.
What is the expected EPS growth for IDEXX LABORATORIES INC (IDXX) stock?
The Earnings per Share (EPS) of IDEXX LABORATORIES INC (IDXX) is expected to grow by 13.36% in the next year.